- Home
- / Compass Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Compass Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.7
2024-10-29
Market Capitalization
$233.9 M
2024-10-29
Revenue
$850 K
FY, 2024
CreditSafe Score
?
Score changed on Jul 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 850.0K | |||||||
| General and administrative expense | 32.8K | 32.1K | 12.9M | 10.9M | 11.7M | 12.2M | 15.1M | 16.9M |
| Operating expense total | 32.8K | 32.1K | 27.8M | 31.3M | 41.7M | 57.5M | 72.8M | |
| EBIT | (32.8K) | (32.1K) | (27.8M) | (81.9M) | (41.7M) | (50.4M) | (56.6M) | (72.8M) |
| EBIT margin, % | -6661.8% | |||||||
| Interest income | 88.0K | 29.0K | 2.4M | 7.9M | 7.3M | |||
| Interest expense | 3.3K | 5.4K | 908.0K | 370.0K | ||||
| Pre tax profit | (29.5M) | (82.2M) | (39.2M) | (42.5M) | ||||
| Income tax expense | 32.0K | |||||||
| Net Income | (36.0K) | (37.5K) | (29.5M) | (82.2M) | (39.2M) | (42.5M) | (49.4M) | (66.5M) |